Altimmune
Today, June 18, 2024, Altimmune (ALT) announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84thScientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

Details for the oral presentations are as follows:

Session Title:
Leveling Up . . .